vs
Side-by-side financial comparison of Varex Imaging Corp (VREX) and Westrock Coffee Co (WEST). Click either name above to swap in a different company.
Westrock Coffee Co is the larger business by last-quarter revenue ($339.5M vs $209.6M, roughly 1.6× Varex Imaging Corp). Varex Imaging Corp runs the higher net margin — 1.1% vs -6.6%, a 7.7% gap on every dollar of revenue. On growth, Westrock Coffee Co posted the faster year-over-year revenue change (48.3% vs 4.9%). Westrock Coffee Co produced more free cash flow last quarter ($27.8M vs $-26.8M). Over the past eight quarters, Westrock Coffee Co's revenue compounded faster (32.8% CAGR vs 0.8%).
Varex Imaging Corp is a global supplier of advanced imaging components and solutions, including X-ray tubes, digital flat panel detectors, and image processing software. Its products serve medical imaging, radiation oncology, and industrial non-destructive testing segments, with customers across key global markets.
Westrock Coffee Co is a global integrated coffee, tea and functional beverage solutions provider. It sources, roasts, manufactures and distributes coffee products, ready-to-drink beverages and custom formulations for retail, foodservice and commercial clients across North America and other key markets.
VREX vs WEST — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $209.6M | $339.5M |
| Net Profit | $2.3M | $-22.6M |
| Gross Margin | 33.3% | 11.5% |
| Operating Margin | 7.3% | -2.6% |
| Net Margin | 1.1% | -6.6% |
| Revenue YoY | 4.9% | 48.3% |
| Net Profit YoY | 866.7% | 8.3% |
| EPS (diluted) | $0.05 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $209.6M | — | ||
| Q4 25 | $228.9M | $339.5M | ||
| Q3 25 | $203.0M | $354.8M | ||
| Q2 25 | $212.9M | $280.9M | ||
| Q1 25 | $199.8M | $213.8M | ||
| Q4 24 | — | $229.0M | ||
| Q3 24 | $205.7M | $220.9M | ||
| Q2 24 | $209.1M | $208.4M |
| Q1 26 | $2.3M | — | ||
| Q4 25 | $12.2M | $-22.6M | ||
| Q3 25 | $-89.1M | $-19.1M | ||
| Q2 25 | $6.9M | $-21.6M | ||
| Q1 25 | $-300.0K | $-27.2M | ||
| Q4 24 | — | $-24.6M | ||
| Q3 24 | $-51.1M | $-14.3M | ||
| Q2 24 | $1.4M | $-17.8M |
| Q1 26 | 33.3% | — | ||
| Q4 25 | 34.0% | 11.5% | ||
| Q3 25 | 33.3% | 11.7% | ||
| Q2 25 | 36.0% | 14.7% | ||
| Q1 25 | 34.3% | 13.6% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | 32.6% | 16.8% | ||
| Q2 24 | 32.0% | 19.9% |
| Q1 26 | 7.3% | — | ||
| Q4 25 | 8.6% | -2.6% | ||
| Q3 25 | -39.8% | -2.4% | ||
| Q2 25 | 10.4% | -5.3% | ||
| Q1 25 | 5.6% | -6.1% | ||
| Q4 24 | — | -4.3% | ||
| Q3 24 | 5.3% | -5.8% | ||
| Q2 24 | 4.4% | -7.9% |
| Q1 26 | 1.1% | — | ||
| Q4 25 | 5.3% | -6.6% | ||
| Q3 25 | -43.9% | -5.4% | ||
| Q2 25 | 3.2% | -7.7% | ||
| Q1 25 | -0.2% | -12.7% | ||
| Q4 24 | — | -10.7% | ||
| Q3 24 | -24.8% | -6.5% | ||
| Q2 24 | 0.7% | -8.5% |
| Q1 26 | $0.05 | — | ||
| Q4 25 | $0.29 | $-0.22 | ||
| Q3 25 | $-2.15 | $-0.20 | ||
| Q2 25 | $0.17 | $-0.23 | ||
| Q1 25 | $-0.01 | $-0.29 | ||
| Q4 24 | — | $-0.26 | ||
| Q3 24 | $-1.25 | $-0.16 | ||
| Q2 24 | $0.03 | $-0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $125.6M | $49.9M |
| Total DebtLower is stronger | $367.6M | $444.1M |
| Stockholders' EquityBook value | $476.9M | $-1.9M |
| Total Assets | $1.1B | $1.2B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $125.6M | — | ||
| Q4 25 | $155.1M | $49.9M | ||
| Q3 25 | $152.6M | $34.0M | ||
| Q2 25 | $223.0M | $44.0M | ||
| Q1 25 | $212.6M | $33.1M | ||
| Q4 24 | — | $26.2M | ||
| Q3 24 | $200.5M | $22.4M | ||
| Q2 24 | $190.0M | $24.3M |
| Q1 26 | $367.6M | — | ||
| Q4 25 | $367.5M | $444.1M | ||
| Q3 25 | $367.5M | — | ||
| Q2 25 | $567.2M | — | ||
| Q1 25 | $567.0M | — | ||
| Q4 24 | — | $393.1M | ||
| Q3 24 | $443.4M | — | ||
| Q2 24 | $443.1M | — |
| Q1 26 | $476.9M | — | ||
| Q4 25 | $472.6M | $-1.9M | ||
| Q3 25 | $455.3M | $11.4M | ||
| Q2 25 | $549.7M | $18.2M | ||
| Q1 25 | $540.2M | $71.4M | ||
| Q4 24 | — | $97.5M | ||
| Q3 24 | $529.1M | $110.3M | ||
| Q2 24 | $581.2M | $81.5M |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.4B | $1.2B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $1.2B | $1.1B | ||
| Q2 24 | $1.3B | $1.1B |
| Q1 26 | 0.77× | — | ||
| Q4 25 | 0.78× | — | ||
| Q3 25 | 0.81× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | 4.03× | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.76× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.1M | $36.7M |
| Free Cash FlowOCF − Capex | $-26.8M | $27.8M |
| FCF MarginFCF / Revenue | -12.8% | 8.2% |
| Capex IntensityCapex / Revenue | 5.1% | 2.6% |
| Cash ConversionOCF / Net Profit | -7.00× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.3M | $-107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $-16.1M | — | ||
| Q4 25 | $7.9M | $36.7M | ||
| Q3 25 | $7.7M | $-26.6M | ||
| Q2 25 | $16.6M | $-7.0M | ||
| Q1 25 | $9.5M | $-22.1M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | $25.9M | $-332.0K | ||
| Q2 24 | $8.0M | $-23.7M |
| Q1 26 | $-26.8M | — | ||
| Q4 25 | $2.3M | $27.8M | ||
| Q3 25 | $1.4M | $-44.7M | ||
| Q2 25 | $9.8M | $-27.5M | ||
| Q1 25 | $5.3M | $-63.4M | ||
| Q4 24 | — | $-15.4M | ||
| Q3 24 | $19.9M | $-36.7M | ||
| Q2 24 | $3.3M | $-59.9M |
| Q1 26 | -12.8% | — | ||
| Q4 25 | 1.0% | 8.2% | ||
| Q3 25 | 0.7% | -12.6% | ||
| Q2 25 | 4.6% | -9.8% | ||
| Q1 25 | 2.7% | -29.7% | ||
| Q4 24 | — | -6.7% | ||
| Q3 24 | 9.7% | -16.6% | ||
| Q2 24 | 1.6% | -28.7% |
| Q1 26 | 5.1% | — | ||
| Q4 25 | 2.4% | 2.6% | ||
| Q3 25 | 3.1% | 5.1% | ||
| Q2 25 | 3.2% | 7.3% | ||
| Q1 25 | 2.1% | 19.3% | ||
| Q4 24 | — | 7.9% | ||
| Q3 24 | 2.9% | 16.5% | ||
| Q2 24 | 2.2% | 17.4% |
| Q1 26 | -7.00× | — | ||
| Q4 25 | 0.65× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.41× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.71× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VREX
| Medical Segment | $144.8M | 69% |
| Industrial Segment | $64.8M | 31% |
WEST
| Coffee And Tea | $202.6M | 60% |
| Flavors Extracts And Ingredients | $69.6M | 21% |
| Sustainable Sourcing And Traceability Segments | $66.9M | 20% |
